These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. Karn T; Pusztai L; Holtrich U; Iwamoto T; Shiang CY; Schmidt M; Müller V; Solbach C; Gaetje R; Hanker L; Ahr A; Liedtke C; Ruckhäberle E; Kaufmann M; Rody A PLoS One; 2011; 6(12):e28403. PubMed ID: 22220191 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients. Peng W; Tang W; Li JD; He RQ; Luo JY; Chen ZX; Zeng JH; Hu XH; Zhong JC; Li Y; Ma FC; Xie TY; Huang SN; Ge LY PeerJ; 2022; 10():e13708. PubMed ID: 35846880 [TBL] [Abstract][Full Text] [Related]
7. A novel prognostic two-gene signature for triple negative breast cancer. Alsaleem MA; Ball G; Toss MS; Raafat S; Aleskandarany M; Joseph C; Ogden A; Bhattarai S; Rida PCG; Khani F; Davis M; Elemento O; Aneja R; Ellis IO; Green A; Mongan NP; Rakha E Mod Pathol; 2020 Nov; 33(11):2208-2220. PubMed ID: 32404959 [TBL] [Abstract][Full Text] [Related]
8. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558 [TBL] [Abstract][Full Text] [Related]
9. Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics. Sheng DL; Shen XG; Shi ZT; Chang C; Li JW Eur Radiol; 2022 Oct; 32(10):6575-6587. PubMed ID: 35759017 [TBL] [Abstract][Full Text] [Related]
10. Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer. Ding R; Wang Y; Fan J; Tian Z; Wang S; Qin X; Su W; Wang Y Front Oncol; 2023; 13():1108472. PubMed ID: 37377907 [TBL] [Abstract][Full Text] [Related]
11. Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer. Lv X; He M; Zhao Y; Zhang L; Zhu W; Jiang L; Yan Y; Fan Y; Zhao H; Zhou S; Ma H; Sun Y; Li X; Xu H; Wei M Cancer Cell Int; 2019; 19():172. PubMed ID: 31297036 [TBL] [Abstract][Full Text] [Related]
12. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982 [TBL] [Abstract][Full Text] [Related]
13. Expression of ROR1 has prognostic significance in triple negative breast cancer. Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of novel three-long noncoding RNA signatures as a diagnostic and prognostic biomarkers of human triple-negative breast cancer. Fan CN; Ma L; Liu N J Cell Biochem; 2019 Mar; 120(3):3185-3196. PubMed ID: 30203490 [TBL] [Abstract][Full Text] [Related]
15. Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers. Liu D Breast Cancer Res Treat; 2020 Aug; 183(1):95-105. PubMed ID: 32601968 [TBL] [Abstract][Full Text] [Related]
16. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study. Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255 [TBL] [Abstract][Full Text] [Related]
17. High expression of TLR3 in triple-negative breast cancer predicts better prognosis-data from the Fudan University Shanghai Cancer Center cohort and tissue microarrays. Fan L; Sui XY; Jin X; Zhang WJ; Zhou P; Shao ZM BMC Cancer; 2023 Apr; 23(1):298. PubMed ID: 37005579 [TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959 [TBL] [Abstract][Full Text] [Related]
19. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer. Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988 [TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer. Liu Z; Ding M; Qiu P; Pan K; Guo Q Front Immunol; 2023; 14():1200282. PubMed ID: 37520534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]